<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: This study sought to compare the effects of <z:chebi fb="0" ids="6904">metoprolol</z:chebi> and <z:chebi fb="0" ids="3441">carvedilol</z:chebi> in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy) study </plain></SENT>
<SENT sid="1" pm="."><plain>BACKGROUND: The impact of beta-blockers in <z:hpo ids='HP_0001635'>heart failure</z:hpo> (HF) patients with devices is uninvestigated </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: <z:hpo ids='HP_0000001'>All</z:hpo> patients receiving either <z:chebi fb="0" ids="6904">metoprolol</z:chebi> or <z:chebi fb="0" ids="3441">carvedilol</z:chebi> in the MADIT-CRT study were identified and compared </plain></SENT>
<SENT sid="3" pm="."><plain>Time-dependent Cox proportional hazard regression analyses were performed to assess differences in hospitalization for HF or <z:hpo ids='HP_0011420'>death</z:hpo> and <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Hospitalization for HF or <z:hpo ids='HP_0011420'>death</z:hpo> occurred in 30% of the patients on <z:chebi fb="0" ids="6904">metoprolol</z:chebi> and in 23% on <z:chebi fb="0" ids="3441">carvedilol</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment with <z:chebi fb="0" ids="3441">carvedilol</z:chebi> was associated with a significantly decreased risk of hospitalization for HF or <z:hpo ids='HP_0011420'>death</z:hpo> when compared with <z:chebi fb="0" ids="6904">metoprolol</z:chebi> (hazard ratio [HR]: 0.70, [95% confidence interval (CI): 0.57 to 0.87], p = 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>This reduction in risk was further attenuated in the subgroup of cardiac resynchronization therapy with implantable cardioverter-defibrillator (CRT-D) patients (HR: 0.61 [95% CI: 0.46 to 0.82], p = 0.001) and CRT-D patients with <z:hpo ids='HP_0011713'>left bundle branch block</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e>) (HR: 0.51 [95% CI: 0.35 to 0.76], p &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0004308'>Ventricular arrhythmias</z:hpo> occurred in 26% and in 22%, respectively, of the patients receiving <z:chebi fb="0" ids="6904">metoprolol</z:chebi> or <z:chebi fb="0" ids="3441">carvedilol</z:chebi> (HR: 0.80 [95% CI: 0.63 to 1.00], p = 0.050) </plain></SENT>
<SENT sid="8" pm="."><plain>General use of beta-blockers and adherence in this study was high, and a clear dose-dependent relationship was found in <z:chebi fb="0" ids="3441">carvedilol</z:chebi>, but not in <z:chebi fb="0" ids="6904">metoprolol</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: In HF patients in New York Heart Association functional class I and II and with wide QRS complexes, <z:chebi fb="0" ids="3441">carvedilol</z:chebi> was associated with a 30% reduction in hospitalizations for HF or <z:hpo ids='HP_0011420'>death</z:hpo> when compared with <z:chebi fb="0" ids="6904">metoprolol</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>A novel beneficial and synergistic effect of <z:chebi fb="0" ids="3441">carvedilol</z:chebi> was seen in patients with CRT-D and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Furthermore, we found a pronounced dose-dependent relationship in <z:chebi fb="0" ids="3441">carvedilol</z:chebi>, but not in <z:chebi fb="0" ids="6904">metoprolol</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>(MADIT-CRT: Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy; NCT00180271) </plain></SENT>
</text></document>